Filing summary
Registrant and period: The supplied filing is Ekso Bionics Holdings, Inc.’s Form 10-K for the fiscal year ended December 31, 2021—not a filing for Chronoscale Holdings Corp. or a standalone fourth quarter. Unless otherwise noted, financial amounts below are in U.S. dollars.
Business context
Ekso designs and sells exoskeleton products for medical rehabilitation and industrial uses. Its EksoHealth segment sells rehabilitation devices and related services; EksoWorks sells industrial exoskeletons and tools. The company reported shipping more than 520 EksoNR and EksoGT devices combined to over 400 rehabilitation facilities or customers worldwide as of year-end. It booked 80 EksoNR units in 2021 and said it shifted medical sales toward subscriptions and away from rentals.
Financial performance
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Revenue | $11.246 million | $8.882 million | Up 27% |
| Gross profit | $6.749 million | $5.070 million | Up 33% |
| Gross margin | 60% | 57% | Up 3 percentage points |
| Operating loss | $13.828 million | $13.291 million | Loss widened |
| Net loss | $9.764 million | $15.825 million | Loss narrowed |
| Cash used in operations | $11.156 million | $8.755 million | Use increased |
EksoHealth revenue was $9.750 million, versus $8.066 million; EksoWorks revenue was $1.496 million, versus $0.816 million. Management attributed higher revenue mainly to increased device sales as business conditions recovered from COVID-19 disruptions. Gross-margin improvement primarily reflected better EksoWorks margins, including lower EVO production costs.
The narrower net loss did not reflect improved operating profitability: it included a $3.962 million noncash gain from revaluing warrant liabilities and $1.099 million from PPP loan forgiveness. The company’s operating loss increased as total operating expenses rose 12% to $20.577 million, including higher general and administrative costs.
Liquidity, debt and capital
- Year-end cash was $40.406 million, up from $12.862 million; working capital was $40.9 million, compared with $13.4 million.
- After $2.0 million of cash subject to the lender’s minimum-cash covenant, management estimated unrestricted cash at $38.4 million and said it was sufficient to fund operations beyond one year from issuance of the statements.
- Cash provided by financing was $38.712 million, principally from the February 2021 public offering, which generated $36.5 million in net proceeds, plus ATM share sales and warrant exercises. Operating activities used $11.156 million.
- Net notes payable were $1.993 million at year-end. The $2.0 million Pacific Western Bank term loan is due in August 2023, is secured by substantially all assets other than intellectual property, and includes covenants and restrictions. The PPP loan and accrued interest were forgiven in June 2021.
- Shares outstanding increased from 8.349 million to 12.693 million during 2021. The filing also reports outstanding warrants and equity awards that may dilute shareholders.
Outlook, risks and notable items
- The filing provides no specific revenue, earnings or cash-flow guidance. Management’s liquidity assessment assumes current resources and continued business development; it also states that sustained losses may continue unless revenue grows substantially.
- COVID-19 continued to affect customer access, rehabilitation-facility priorities and capital spending. Management reported some recovery in demand but said the pandemic’s future effects were uncertain.
- Supply-chain shortages and longer lead times for semiconductors, batteries, metals, plastics and manufacturing services could raise costs or delay deliveries. The company also relies on some single-source suppliers and has no long-term supply agreements for many components.
- Ekso describes its markets as emerging, with long sales cycles, challenging hospital capital approvals, uncertain adoption and reimbursement, and significant competition. It has incurred losses each year since inception and had an accumulated deficit of $208.9 million at year-end.
- Health Canada reclassified EksoNR from Class I to Class II in November 2021 and required a new medical-device license application. The company said it was restricted from marketing there until registration and expected resolution by early 2023.
- After year-end, CEO Jack Peurach resigned; Steven Sherman became CEO and Scott Davis became President and COO on January 21, 2022. The company agreed to severance payments and accelerated vesting of certain RSUs.
- The auditor highlighted revenue recognition as a critical audit matter, involving judgments about distinct performance obligations, allocation of contract prices and timing of recognition. The 2021 financial statements received an unqualified audit opinion. Management assessed disclosure controls and internal control over financial reporting as effective; the auditor was not engaged to attest to internal-control effectiveness.
Most important facts for investors to verify
- Confirm that Ekso Bionics Holdings, Inc. is the intended issuer, given the mismatch with the request metadata.
- Review the audited statements and cash-flow trend, particularly operating cash use, operating losses and the assumptions behind management’s liquidity assessment.
- Assess the sustainability of revenue growth and gross-margin gains, including device-versus-subscription mix, customer adoption and the long sales cycle.
- Check subsequent filings for progress on Health Canada registration, supply constraints, leadership transition and any updated outlook.
- Evaluate potential dilution from warrants, stock options, restricted stock units, the ATM program and future equity financing.